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Objectives: We evaluated mid-term results of the multicenter EVT/Guidant aortouniiliac endograft (AI) trial and
ascertained the durability of this endovascular technique in patients unable to undergo standard bifurcated endografting.
Methods: From November 1996 to December 1998, 121 patients were enrolled to receive the AI device on the basis of
complex iliac artery anatomy contraindicating bifurcated endografting. Clinical data were centrally collected, and
radiographic data were evaluated by core facility.
Results: AI placement was technically successful in 113 of 121 patients. At operation, patients who underwent AI had
significantly more arrhythmias, congestive heart failure, and peripheral occlusive disease (P < .05) compared with patients
who underwent open aneurysmorrhaphy in the EVT/Guidant trials, indicating comorbid features in this anatomic
cohort. Distal AI attachment was performed to the external iliac artery in 40 (36%) patients. Median follow-up was 38
months. In the AI group, overall aneurysm diameter decreased over the duration of study from 54.4  9.6 mm to 44.4
 16.4 mm (P  .004). At 24 and 36 months after repair, reduction in aneurysm size was associated with absence of
endoleak (P .003 and P .008, respectively). Aneurysms shrunk or remained stable in 109 (96.5%) patients. Endoleak
was identified in 52.3% of patients at discharge, and at follow-up in 30.9% at 1 year, 34.8% at 2 years, 28.6% at 3 years,
and 30.4% at 4 years. Type II endoleak predominated. Leak from failure to completely occlude contralateral iliac flow
accounted for 8 of 58 endoleaks (13.8%) at discharge. Sixteen patients (14.2%) underwent postoperative endoleak
treatment; in one of these patients open conversion was necessary at 20 months. Post-procedure thigh or buttock
claudication developed in 16 patients (14.2%). Thirteen patients (81.3%) had either distal attachment in the external iliac
artery or contralateral type IIA occlusion. Fifteen patients (13.3%) required intervention because of reduced limb flow;
one of these patients underwent open conversion at 27 months, and another underwent axillofemoral grafting at 28
months. Device migration was confirmed in 2 (1.8%) patients, without current clinical sequelae. Whereas no femoro-
femoral graft thromboses occurred, graft infection developed in 3 patients (2.6%). During follow-up, aneurysm in 2
patients ruptured. Late death occurred in 41 patients (36.3%). Twenty-four patients (58.5%) died of cardiopulmonary
disease; one death was endograft-related after aneurysm rupture; and one death was related to femorofemoral bypass
infection. Actuarial survival was 78.4% (95% confidence interval [CI], 71%-86%) at 2 years and 63.4% (95% CI, 54%-73%)
at 4 years.
Conclusions: In patients with significant comorbid conditions and complex iliac anatomy unfavorable for bifurcated
endografting, AI with femorofemoral bypass grafting is safe and effective. In most patients this endovascular option
provides satisfactory mid-term results. (J Vasc Surg 2003;37:1142-9.)
Since the introduction of endovascular repair of ab-
dominal aortic aneurysm, a major limitation to the vascular
surgeon’s ability to use these methods has been anatomic
constraints of the aneurysm. One of these constraints con-
tinues to be complex iliac artery anatomy. Specifically, an
ectatic or frankly aneurysmal iliac artery, as well as iliac
tortuosity or occlusive disease, may lead to inadequate
graft-vessel landing zones or difficulty in tracking and plac-
ing endovascular devices.
In such circumstances, some iliac limitations of endo-
vascular repair may be overcome with an aortouniiliac (AI)
device in conjunction with femorofemoral crossover bypass
grafting when one iliac artery is suitable for access and
device deployment. Several studies have confirmed the
feasibility and short-term success of placing such a repair
configuration.1-4 Further, the US Food and Drug Admin-
istration (FDA) has recently approved the EVT/Guidant
AI device for use in such cases. However, several questions
remain regarding late success after placement of this en-
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dograft configuration and have tempered enthusiasm for its
use. The durability of femorofemoral bypass grafting is
poorly defined in this patient population and remains sus-
pect. The significance of altered pelvic perfusion with vari-
ous forms of internal iliac artery exclusion also remains
undefined. Finally, the durability of contralateral common
or combined external-internal iliac artery occlusion re-
quired during repair remains unclear, inasmuch as endoleak
and distal embolization are conceivable consequences. In
addition to these end points unique to AI with femoro-
femoral bypass, aneurysm enlargement, rupture, endoleak,
reduced limb flow, and associated repeated interventions,
as well as late death, are clearly important in patients with
aneurysm treated with endografting. Therefore, in an at-
tempt to better address these concerns, this report presents
the continuing mid-term follow-up of the EVT/Guidant
AI device trial.
PATIENTS AND METHODS
Description of the EVT/Guidant AI device, implanta-
tion technique, and patient selection, with inclusion and
exclusion criteria, as well as the follow-up protocol for this
trial and 12-month outcome, have been published.4 The AI
device is a unibody graft that tapers from the aortic anchor-
ing segment to a single iliac graft limb (Fig 1). The graft is
made of woven polyester with elgiloy self-expanding,
hooked anchoring stents, which are balloon dilated after
deployment to enhance vessel wall attachment. The mid-
graft and limb are not supported. The limb is crimped to aid
in patency with angulation. Trial enrollment was carried
out between November 1996 and December 1998 under
an Investigational Device Exemption approved by the
FDA. Patients enrolled were not candidates for bifurcated
endografting, because of significant iliac aneurysm disease
or other iliac artery anatomic constraints.
Anatomic inclusion criteria were an ipsilateral iliac ar-
tery segment 2.5 cm or more in length that was not
aneurysmal or atherosclerotic, to enable proper attach-
ment; one ipsilateral femoral or iliac artery permitting ac-
cess with a 23F (7.7 mm) device; and a contralateral fem-
oral or iliac artery permitting access with a 16F (5.3 mm)
device if common iliac artery occlusion was required. Ana-
tomic exclusion criteria were a contralateral iliofemoral
system also acceptable for bifurcated endografting or antic-
ipated loss of adequate pelvic circulation with necessary
internal iliac artery occlusion. Patients were required to be
acceptable candidates for open aneurysmorrhaphy and to
have at least a 2-year anticipated life expectancy, based on
the medical judgment of each enrolling investigator. In
addition to iliac anatomy enabling access and deployment
in one iliac system, requirements included infrarenal neck
length at least 15 mm and diameter no larger than 26 mm.
Relative contraindications to placement, considered indi-
vidually for each patient, were calcification, extensive mural
thrombus, and angulation of the proximal aneurysm neck.
Ipsilateral sides were chosen such that landing in the com-
mon iliac artery was preferred if feasible. If landing in the
external iliac artery was required distally, the ipsilateral
internal iliac artery was coil-embolized to prevent endoleak.
By protocol, at least one internal iliac artery was to remain
patent. Contralateral iliac system occlusion was performed
with either endoluminal common iliac artery occlusion
with coils or a covered stent (ENDOSOC; Guidant, Menlo
Park, Calif) or a combination of external and internal iliac
artery occlusion, with catheter-based internal iliac artery
occlusion with surgical external iliac artery ligation from the
femoral incision.
Procedures were performed in the operating room or
interventional suite with appropriate operating room staff,
equipment, and capability. The AI with femorofemoral
crossover configuration was accomplished with surgical
exposure of the femoral arteries bilaterally. After ipsilateral
sheath and wire placement, appropriate aortic and iliofem-
oral arteriography, and systemic heparinization, a longitu-
dinal common femoral artery arteriotomy was performed,
and the AI device sheath was advanced over a super-stiff
guide wire and the device deployed under fluoroscopic
guidance. The proximal and distal attachments, as well as
Fig 1. EVT/Guidant aortouniiliac device.
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the graft limb, were balloon dilated to secure the device and
fully expand the limb to eliminate any kinking or compres-
sion secondary to diseased or tortuous native iliac vessels.
The sheath and guide wire were removed, and the ipsilat-
eral anastomosis of the femorofemoral crossover bypass
graft was performed, with subsequent restoration of ipsilat-
eral leg blood flow. Proximal iliac occlusion was performed
endovascularly, with subsequent completion of the femo-
rofemoral distal anastomosis to a longitudinal contralateral
common femoral arteriotomy. Completion arteriography
was performed to check attachment site, AI limb, femoro-
femoral graft, and contralateral iliac system status.
At discharge, 6 months, and annually thereafter, all
patients underwent abdominal plain film radiography, graft
duplex ultrasound scanning, ankle-brachial index measure-
ment, and fine-cut contrast-enhanced computed tomogra-
phy (CT), along with physical examination. If primary
endoleak was present, CT was performed at 3 months after
the procedure. Independent examiners at The Cleveland
Clinic core laboratory reviewed all images.
All data, including late adverse events, were recorded
on trial forms as specified by the FDA and were audited for
completeness and accuracy. Analyses that involved dichot-
omous variables were performed with the Fisher exact test.
Continuous variables were evaluated with the Student t
test. Actuarial analysis of mortality was performed with the
Kaplan-Meier method.
RESULTS
In all, 121 patients from 15 investigational sites (Ap-
pendix) were enrolled in the AI trial; 112 patients (92.6%)
were men. As reported by Moore et al,4 intraoperative
conversion was necessary in 4 (3.3%) patients. Treatment
was abandoned in 3 patients (2.5%), and 1 (0.8%) patient
died during surgery. Thus AI device placement was techni-
cally successful in 113 patients, who were available for
long-term follow-up per protocol to evaluate graft durabil-
ity. Moore et al4 also summarized 30-day mortality (4.2%)
and delineated early adverse post-repair events in this
group. At repair, mean age of this cohort was 72.8  7.0
years. As of this writing, mean follow-up is 36.2  16.7
months (median, 38.0 months).
At the time of the procedure, significantly more pa-
tients in the AI cohort had congestive heart failure (17.4%
vs 7.2%; P  .03), cardiac arrhythmias (37.8% vs 18.9%; P
 .002) and peripheral arterial occlusive disease (25.6% vs
10.8%; P  .004) compared with 111 control patients
undergoing open aneurysmorrhaphy in the EVT/Guidant
trials (Table I, online only). Mean initial aneurysm diame-
ter in the AI cohort was 54.4  9.6 mm, and in 25 of 113
patients (22%) initial aneurysm diameter was less than 50
mm, as recorded by the enrolling investigators. Five specific
deployment configurations were used during the trial (Fig
2). The most common (n  54) consisted of distal CIA
Fig 2. Configurations of deployment and contralateral occlusion in EVT/Guidant aortouniilac endograft trial.
Configuration data are unavailable for three patients.
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landing with contralateral CIA occlusion. In order of de-
creasing frequency the remainder were configured with
distal external iliac artery landing with contralateral com-
mon iliac artery occlusion (n  32), distal common iliac
artery landing with contralateral external and internal iliac
artery occlusion (n 13), distal external iliac artery landing
with contralateral occlusion of the external and internal iliac
arteries (n  6), and any landing zone with preexisting
contralateral occlusion (n  5). Distal attachment was
performed in the external iliac artery in 40 patients (36%).
Thus active, contralateral iliac system occlusion was neces-
sary at endografting in 105 patients. Five patients required
no active, therapeutic embolization because of preexisting
chronic occlusion, and no patient underwent preoperative
therapeutic contralateral iliac system occlusion. Data were
not available for 3 patients. Methods of contralateral occlu-
sion were the EVT/Guidant ENDOSOC in 62 of 105
patients, other catheter-based methods in 25 patients, and
surgical ligation of the external iliac artery in 18 patients.
Preexisting contralateral occlusion was present in 5 pa-
tients, and data were not available for 3 patients.
During 48 months of post-procedural follow-up, over-
all aneurysm diameter decreased, from 54.4  9.6 mm to
44.4  16.4 mm (Table II, online only). Among 22
patients with data at both discharge and 48 months, mean
overall aneurysm diameter decreased significantly, from
54.4  11.9 mm to 45.5  16.1 mm (P  .004). Aneu-
rysm size reduction appears to stabilize 2 years after repair.
Thus far, increased aneurysm diameter (5 mm) is present
in 3.1% of patients at 1 year after repair, 3% of patients at 2
years, 4.2% of patients at 3 years, and 9.1% of patients at 4
years (Fig 3). Significant aneurysm expansion (5 mm)
developed after discharge in 4 patients, within 12 months
in 3 patients and at 48 months in 1 patient. Thus 96.5% of
aneurysms shrunk or remained stable. Although the inci-
dence of significant aneurysm expansion was small, the
absence of endoleak of any kind was associated with aneu-
rysm size reduction of 5 mm or more at 24-month fol-
low-up (P  .002) and 36-month follow-up (P  .008).
Endoleak of any type was present in 52.3% of patients at
discharge, 30.9% of patients at 1 year after repair, 34.8% of
patients at 2 years, 28.6% of patients at 3 years, and 30.4%
of patients at 4 years. Breakdown of endoleak by specific
type is presented in Table III. Type II endoleak represents
the majority. Leak from the therapeutic, active contralateral
occlusion was present in 8 patients (7.2%) at discharge and
in no patients after 36 months. All endoleaks sealed spon-
taneously without repeated intervention.
Repeated intervention because of endoleak or aneu-
rysm enlargement was required in 17 patients (15%) over
the 4-year follow-up, between 31 days and 1 year post-
procedure in 6 patients, between 1 and 2 years in 5 patients,
between 2 and 3 years in 4 patients, and after 3 years in 3
patients. In 1 patient with type II endoleak treated with coil
embolization of the feeding lumbar arteries at 1 month
post-repair, conversion to open reconstruction was neces-
sary in month 20 because of continued leak and significant
aneurysm enlargement, from 57 mm at initial endografting
to 65 mm at conversion.
To date, migration of two devices has been confirmed
by the core laboratory. In both cases the device moved
caudad to the superior attachment site by 10 to 12 mm
within the first year after placement. Neither patient has
experienced endoleak or any clinical sequelae as a result of
device migration. In 1 patient graft infection of the AI
prosthesis developed and was treated with long-term anti-
biotic therapy. To date this infection has remained indo-
lent. In 2 patients (1.8%) the aneurysm ruptured. The first
patient had severe back and abdominal pain 58 months
after initial repair. Follow-up examination at 48 months
showed no endoleak and aneurysm regression. Six months
later, the patient underwent cardiac catheterization, and
the aneurysm ruptured 2 months later. Evaluation at rup-
ture revealed ipsilateral iliac dissection and the remaining
endograft in good position. It is believed the dissection
disrupted the distal attachment site, leading to flow into the
aneurysm sac. A covered stent was placed across the iliac
artery endovascularly to seal the dissection entry, and the
patient has done well since. The second rupture occurred
64 months after initial AI placement in a 93-year- old
patient with abdominal pain. Follow-up imaging revealed a
type II endoleak at 24 months, which resolved without
intervention and has not been demonstrated since. The
aneurysm had significantly decreased in size; however, the
ipsilateral iliac artery had become aneurismal, leading to
disruption of the distal attachment site, with retrograde
aortic aneurysm filling and rupture. Endovascular stenting
was used to bridge the distal attachment site disruption.
The patient had acute respiratory distress syndrome post-
operatively and was discharged to a skilled nursing facility,
but died 3 weeks later.
Reduction in limb flow occurred in 15 (13.3%) pa-
tients. Eight patients (7.1%) required repeated interven-
Fig 3. Changes from baseline aneurysm diameter at core lab
evaluation of follow-up imaging after EVT/Guidant aortouniiliac
endografting with femorofemoral crossover bypass grafting.
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tion, ie, limb angioplasty and stenting, within 30 days
postoperatively. Thus far, none of these patients has re-
quired further repeated intervention to assist subsequent
limb patency. After 1 month, 7 patients (6.2%) required
repeated intervention with limb angioplasty and stenting
because of reduced limb flow. Two of these 7 patients have
required further repeated intervention. In 1 patient with
thigh-buttock claudication, endovascular intervention was
performed in post-procedure month 24 and again in month
25. Subsequent conversion to open repair was necessary 27
months after initial placement, because of reduced limb
flow. Another patient with thigh-buttock claudication un-
derwent endovascular intervention because of limb kinking
25 months after initial repair, and then axillofemoral bypass
grafting in month 28. Thus in two of 15 patients (13.3%)
with reduced limb flow eventual operative correction was
necessary.
Thigh or buttock claudication developed in 8 patients
(7.1%) within 30 days of repair and in 8 additional patients
(7.1%) more than 30 days after repair. Most of these
patients (n  13; 81.3%) had either distal landing in the
external iliac artery or occlusion of the contralateral internal
iliac artery. Four of 16 (20%) patients have undergone
intervention specifically because of thigh or buttock clau-
dication after endografting. These interventions were an-
gioplasty and stenting to correct reduced graft limb flow
from limb kinking. Thus four of 15 patients with reduced
limb flow had thigh or buttock claudication. Improvement
has occurred or persistent symptoms have stabilized in all
16 patients. No progression to limb-threatening ischemia
has occurred. No embolization from occluded contralateral
iliac systems has been reported.
Complications directly resulting from femorofemoral
bypass grafting occurred in 3 patients (2.6%), and all were
graft infections. In 1 patient graft infection diagnosed 42
months after repair was treated long-term with antibiotic
agents; however, at 46 months renal failure and cardiac
arrhythmias developed, and the patient ultimately died.
Another patient underwent graft explantation, bilateral
femoral vein patching with cryopreserved human saphe-
nous vein with bilateral sartorius muscle flaps, and con-
tralateral axillofemoral bypass grafting 3 months after initial
AI placement, but died of unrelated causes 123 days after
repair. In the third patient graft infection developed 2
months after initial repair. The femorofemoral graft was
explanted, and contralateral axillopopliteal bypass grafting
was performed. This patient is alive. To date, no femoro-
femoral crossover graft has thrombosed or required revi-
sion.
Late death occurred in 41 patients (36.3%). Cause of
death was cardiovascular in 14 patients (34.1%), pulmonary
in 10 patients (24.4%), cancer in 10 patients (24.4%), and
other cause in 7 patients (17.1%). One endograft-related
death occurred after aneurysm rupture 64 months after AI
placement, and one femorofemoral bypass-related death
occurred 46 months after endografting. Both cases are
described above. Actuarial late survival was 78.5%  3.9%
(95% confidence interval [CI], 71%-86%) at 2 years and
63.4  5.0% (95% CI, 54%-73%) at 4 years (Fig 4).
DISCUSSION
Since Parodi et al5 first described endoluminal treat-
ment of abdominal aortic aneurysm (EVAR) in 1991,
application of the technology has increased dramatically.
While early reports suggested that only about 20% of pa-
tients with abdominal aortic aneurysm would be anatomi-
cally suitable for EVAR, mechanical and design enhance-
ments have increased applicability to 50% to 60% or more of
these patients.6-9 However, it has been estimated that
roughly 50% of patients are excluded from EVAR because
of adverse anatomic characteristics of the iliofemoral arter-
ies.6 If this disadvantageous iliac artery anatomy could be
overcome, perhaps two thirds of patients would be poten-
tial candidates for EVAR if open repair is not considered
Table III. Perigraft flow (endoleak) in patients with AI graft*
Perigraft flow
Follow-up (mo)
Discharge 12 24 36 48
No. of patients with perigraft
flow data in core laboratory
datacut 111 97 69 49 23
n % n % n % n % n %
No perigraft flow 48 43.2 60 61.9 40 58.0 30 61.2 13 56.5
Perigraft flow, all types 58 52.3 30 30.9 24 34.8 14 28.6 7 30.4
Attachment site flow (type I) 8 7.2 4 4.1 1 1.4 1 2.0 0 0.0
Branch flow (type II) 35 31.5 18 18.6 18 26.1 11 22.4 7 30.4
Contralateral occlusion site 8 7.2 5 5.2 2 2.9 0 0.0 0 0.0
Flow type unknown† 7 6.3 3 3.1 3 4.3 2 4.1 0 0.0
Flow indeterminate‡ 5 4.5 7 7.2 5 7.2 5 10.2 3 13.0
Total 111 100 97 100 69 100 49 100 23 100
Data not available for two patients.
*Per core laboratory evaluation.
†Perigraft flow confirmed but type unknown.
‡Image quality precludes endoleak identification.
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optimal. An aortouniiliac prosthesis combined with con-
tralateral lower extremity revascularization with femoro-
femoral crossover bypass grafting could overcome many of
these iliac limitations if one iliac system provides adequate
access and distal attachment site.
Recognized advantages to such a system include ease of
device deployment, without rotational concerns, and no
modular interface requirements and their potential pitfalls.
Also, ease of use broadens EVAR applicability to patients
with ruptured aneurysms.10 Disadvantages unique to this
repair include the potential drawbacks of femorofemoral
bypass grafting, including poor late patency and infection,
and development of thigh or buttock claudication when
pelvic flow is disturbed by either ipsilateral or contralateral
occlusion or alteration in flow. Further, occasional difficul-
ties with therapeutic contralateral iliac system occlusion, eg,
endoleak, may occur.
The feasibility and short-term success of this endovas-
cular configuration have been reported by several au-
thors.1–4 Our institution’s early experience with this en-
dograft option has been reported by Rehring et al.3 Moore
et al4 described the operative and 12-month outcomes in
this EVT/Guidant AI device trial. These authors reported
30-day mortality of 4.2% in this trial and clearly delineated
early morbidity. These accounts have indicated that AI
endografting with femorofemoral crossover grafting can
accomplish aneurysm exclusion and broaden the spectrum
of patients treated endovascularly. However, continued
study of the long-term issues of endograft limb patency,
pelvic perfusion alterations by intentional occlusion of in-
ternal iliac arteries, consequences of contralateral iliac sys-
tem occlusion, and femorofemoral bypass graft durability is
critical to determine the lasting dependability of this type of
repair. The purpose of this report is to continue evaluation
of the recently FDA-approved EVT/Guidant AI device and
the associated femorofemoral crossover graft, to better
understand how its use fits into the treatment options
available to the vascular surgeon.
AI endografting with femorofemoral crossover bypass
grafting can produce adequate aneurysm exclusion post-
procedure, as evident significant overall aneurysm diameter
reduction in this cohort. Aneurysm reduction occurs within
the first 24 months after repair, reaching a stable diameter
afterward. After EVAR the presence of endoleak, specifi-
cally types I and III, has been reported as an independent
risk factor for adverse outcome.11,12 While it is accepted
that a majority of type II leaks will close spontaneously,
their presence can retard aneurysm regression and occa-
sionally lead to rupture.13-15 Although the number of
patients with aneurysm growth in this report is small, a
relationship between endoleak and failure of the aneurysm
to regress is noted after AI with femorofemoral crossover.
Some may consider the rate of endoleak in this trial to be
substantial. Indeed, endoleak was present in more than 50%
of patients at discharge. However, after 12 months en-
doleak was present in 30%, which is more consistent with
our institution’s prior report, which delineated a 22% en-
doleak rate, and other available literature on bifurcated
endografting.3,11,16 Of interest, 17 of 58 initial patients
(29%) with endoleak at discharge later require repeated
intervention, and only 1 patient (1.7%) needed open con-
version. It appears that endoleak can be adequately treated
with catheter-based techniques in patients with this type of
reconstruction configuration, with acceptable mid-term re-
Fig 4. Survival after aortouniiliac endografting with the EVT/Guidant device with femorofemoral bypass grafting.
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sults. Further, the incidence of leak from the contralateral
iliac system occlusion appears small, noted in only 8 pa-
tients (7%) at discharge. Our approach has been to treat
types I, III, and IV endoleaks with endoluminal methods,
because of their clear correlation to poor endograft out-
come, and to observe type II endoleaks unless aneurysm
enlargement occurs or they persist for more than 12
months.
Graft limb problems after EVAR most commonly in-
clude kinking and thrombosis. In our institution’s recently
reported endografting experience, Dattilo et al17 found
limb kinking or thrombosis in some 4% of patients after
primary endografting. Similarly rare results were docu-
mented in the EUROSTAR registry.18 Fairman et al19
reported limb interventions necessary when using the bi-
furcated EVT/Guidant endograft. They found that nearly
40% of patients required either intra-procedure or post-
procedure intervention on graft limbs. The rate of limb
interventions necessary after repair with the bifurcated de-
vice was 11.6%. These authors suggested that prophylactic
stenting of the Ancure system limbs may be warranted.
Postoperative limb interventions with the AI device were
necessary in 15 patients (13.3%) with only one endograft
limb at risk. This is not surprising, and it likely represents
the more complex iliac anatomy in patients with the AI
device, as well as the unsupported limb. In addition, en-
doluminal therapy, eg, thrombolysis or angioplasty and
stenting, was successful in more than 85% of patients with
the AI device with limb compromise, and only 2 patients
with reduced limb flow required operative correction.
Clearly, while patients with the AI device have a higher
complexity of iliac disease, catheter-based interventions for
reduced limb flow can be just as successful as in those with
bifurcated endografts. However, the rate of reduced limb
flow with the AI device in conjunction with required limb
interventions adds validity to the thoughts of Fairman et
al19 regarding the unsupported limbs of the EVT/Guidant
device.
The rate of migration (1.8%) and late aneurysm rupture
(1.8%) in this AI trial is similar to that reported in the
literature.12,16 While migration may limit durability of an
endovascular device, the altered outflow with an AI device
compared with a bifurcated device does not seem to place it
at higher risk for migration. We have not aggressively
treated device migration unless it has caused attachment
site endoleak or led to severe device malformation. Thus
far, AI rupture experience is related to iliac artery disease in
this cohort. In 1 patient iliac artery dissection developed
after catheterization, with subsequent aneurysm rupture,
and in another patient dissection was related to late con-
tinuing iliac artery aneurysm degeneration, with loss of
distal seal integrity, retrograde filling of the aneurysm, and
rupture. These events were probably related to disease
progression rather than to technical device failure. The AI
with femorofemoral crossover configuration does not in-
crease risk for rupture.
AI with femorofemoral crossover, by definition, alters
pelvic blood flow. The potential for buttock claudication
from either intentional internal iliac artery occlusion or
contralateral iliac system occlusion is real. Development
and relative benignity of thigh or buttock claudication after
this type of reconstruction have been reported.2,3 Recently,
Lee et al20 described the real but small risks associated with
internal iliac artery occlusion to facilitate EVAR; thigh or
buttock claudication was most common. The current eval-
uation is clearly corroborative. Although nearly 15% of
patients had thigh or buttock claudication after AI with
femorofemoral crossover, most experienced attenuation or
stabilization of pain, likely related to collateral vessel for-
mation from either cross-pelvic flow or the lumbar and
epigastric vessels. Occlusion of the internal iliac artery
appears to be associated with thigh or buttock claudication,
because 80% of patients with this complication had either
distal landing in the external iliac artery or embolization of
the contralateral internal iliac artery. Either internal iliac
artery revascularization or newer flared iliac limbs that
enable landing proximal to the iliac bifurcation are poten-
tial methods to avert these maneuvers; however, their effect
on pelvic flow and claudication remains unclear.
Initial skepticism for the success of AI endografting
with femorofemoral bypass was also partly due to long-
term results of femorofemoral bypass in patients with lower
extremity occlusive disease.21 However, early patency re-
sults of femorofemoral bypass after EVAR have been en-
couraging.4 In our earlier report of AI placement in 51
patients, 2-year primary patency of the femorofemoral graft
was 97.8%.3 In this trial, no graft thromboses occurred at a
mean of 37 months. This has been attributed to the usually
good distal runoff in patients with aneurysm compared
with those with occlusive disease.22,23 Patency of the femo-
rofemoral crossover bypass graft does not appear to com-
promise late outcome of this reconstruction configuration.
The major complication of femorofemoral grafting in this
trial was infection. According to Rutherford et al22 and
Thompson et al,23 infection occurs in up to 4% to 5% of
patients with this method of revascularization. The 2.6%
infection rate in this trial is similar.
In conclusion, AI endografting in conjunction with
femorofemoral crossover bypass grafting with the EVT/
Guidant device appears safe and effective. Adequate mid-
term aneurysm exclusion can be achieved in most patients,
and most post-repair complications can be treated endovas-
cularly. This reconstruction option offers an effective treat-
ment alternative in patients at high risk for open repair who
have unilateral iliac artery anatomy unsuitable for bifur-
cated endografting. The unique features of this endovascu-
lar reconstruction, in particular femorofemoral grafting and
contralateral iliac system occlusion, do not appear overly
problematic.
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Appendix. EVT/Guidant aortouni-iliac device investigational sites and associated investigators
Investigational site Investigator(s) Aortoiliac
Dartmouth-Hitchcock Medical Center Jack L. Cronenwett, MD, and Mark F. Fillinger, MD 3
East Carolina University David H. Deaton, MD 7
Emory University Hospital Elliot L. Chaikoff, MD, PhD 12
Hospital of the University of Pennsylvania Ronald M. Fairman, MD 3
Massachusetts General Hospital David C. Brewster, MD 23
Montefiore Medical Center Frank J. Veith, MD 6
Miami Cardiac & Vascular Institute Barry T. Katzen, MD 2
Northwestern Medical Center James S. T. Yao, MD, PhD 1
Ochsner Clinic Samuel R. Money, MD 2
University of Pittsburgh Michel S. Makaroun, MD 8
Sentara Norfolk General Hospital Roger T. Gregory, MD 9
Saint Thomas/Vanderbilt William H. Edwards, Jr, MD, and Thomas C. Naslund, MD 14
UCLA Wesley S. Moore, MD 18
Washington University Medical Center Gregorio A. Sicard, MD 12
St Vincent Hospital Malcolm B. Herring, MD 1
Total 121
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